» Articles » PMID: 18647248

Predicting the Short Form-6D Preference-based Index Using the Eight Mean Short Form-36 Health Dimension Scores: Estimating Preference-based Health-related Utilities when Patient Level Data Are Not Available

Overview
Journal Value Health
Publisher Elsevier
Date 2008 Jul 24
PMID 18647248
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective is to derive an algorithm to predict a cohort preference-based short form-6D (short form-6D) score using the eight mean health dimension scores from the short form-36 (SF-36) when patient level data are not available.

Methods: Health-related quality of life data (N = 6890) covering a wide range of health conditions was used to explore the relationship between the SF-6D and the eight health dimension scores. Models obtained using ordinary least square regressions were compared for goodness of fit and predictive abilities on both within-sample subgroups and out-of-sample published data sets.

Results: The models explained more than 83% of the variance in the individual SF-6D scores with a mean absolute error of 0.040. When using mean health dimension scores from within-sample subgroups and out-of-sample published data sets, the majority of predicted scores were well within the minimal important difference (0.041) for the SF-6D.

Conclusions: This article presents a mechanism to estimate a mean cohort preference-based SF-6D score using the eight mean health dimension scores of the SF-36. Using published summary statistics, the out-of-sample validation demonstrates that the algorithms can be used to inform both clinical and economic research. Further research is required in different health conditions.

Citing Articles

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.

Strand V, Bender S, McCabe D Rheumatol Ther. 2024; 11(5):1291-1302.

PMID: 39120847 PMC: 11422532. DOI: 10.1007/s40744-024-00687-w.


A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis.

Chung M, Valenzuela A, Li S, Catanese B, Stevens K, Fiorentino D Rheumatology (Oxford). 2021; 61(6):2441-2449.

PMID: 34718447 PMC: 9308380. DOI: 10.1093/rheumatology/keab810.


Self-Reported Satisfaction to Treatment, Quality of Life and General Health of Type 2 Diabetes Patients with Inadequate Glycemic Control from North-Eastern Romania.

Grigorescu E, Lacatusu C, Cretu I, Floria M, Onofriescu A, Ceasovschih A Int J Environ Res Public Health. 2021; 18(6).

PMID: 33801100 PMC: 8004112. DOI: 10.3390/ijerph18063249.


Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension.

Tran-Duy A, Morrisroe K, Clarke P, Stevens W, Proudman S, Sahhar J J Am Heart Assoc. 2021; 10(7):e015816.

PMID: 33759539 PMC: 8174376. DOI: 10.1161/JAHA.119.015816.


Posture, Gait, Quality of Life, and Hearing with a Vestibular Implant.

Chow M, Ayiotis A, Schoo D, Gimmon Y, Lane K, Morris B N Engl J Med. 2021; 384(6):521-532.

PMID: 33567192 PMC: 8477665. DOI: 10.1056/NEJMoa2020457.